Physician profile
Addy Squarer
NPI 1679581425
$4,783.70
in general payments reported to CMS, 2019-2025
24 companies · $1,428 in 2025
The $1,428 reported for 2025 was more than what 85% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $955 · 2020: $137 · 2021: $483 · 2022: $702 · 2023: $714 · 2024: $364 · 2025: $1,428.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,493 · Education: $13.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,492.93 |
| Education | $13.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $719.28 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $498.18 | 2021-2024 | Farxiga, Lokelma |
| Novo Nordisk INC | $357.88 | 2024-2025 | Ozempic |
| Vifor Pharma, INC. | $287.99 | 2019-2022 | |
| Radius Health, INC. | $245.21 | 2019-2022 | |
| Baxter Healthcare | $220.21 | 2019-2020 | |
| Horizon Therapeutics Plc | $218.23 | 2021-2022 | |
| Medtronic, INC. | $207.96 | 2021-2022 | |
| Travere Therapeutics, INC. | $197.59 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $186.18 | 2019-2025 | Voyxact |
| Abbott Laboratories | $158.48 | 2025 | Freestyle Libre 3 |
| Calliditas Therapeutics US INC. | $145.56 | 2023-2025 | Tarpeyo |
| Vantive US Healthcare LLC | $143.25 | 2025 | Renal - Pd |
| Glaxosmithkline, LLC. | $139.36 | 2020-2024 | Arexvy |
| Bard Peripheral Vascular, INC. | $135.28 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $131.90 | 2019-2021 | |
| Lilly USA, LLC | $124.99 | 2025 | Jardiance |
| Akebia Therapeutics INC | $124.67 | 2025 | Vafseo |
| Teva Pharmaceuticals USA, INC. | $124.60 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $116.44 | 2025 | |
| Boston Scientific Corporation | $110.03 | 2019 | |
| Amgen INC. | $101.09 | 2023 | Prolia |
| Exact Sciences Corporation | $71.97 | 2023-2025 | Cologuard Collection Kit |
| Dexcom, INC. | $17.37 | 2023 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Addy Squarer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.